Sonja Thaler

Mannheim, BW 68167, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Distinct 2-phenylimidazo[1,2-a]pyridine derivatives that inhibit breast cancer cell proliferation identified as AHR ligands.

Distinct 2-phenylimidazo[1,2-a]pyridine derivatives that inhibit breast cancer cell proliferation identified as AHR ligands.

Journal: iScience

Published: October 22, 2025

Detection of Cellular Senescence Reveals the Existence of Senescent Tumor Cells within Invasive Breast Carcinomas and Related Metastases.

Detection of Cellular Senescence Reveals the Existence of Senescent Tumor Cells within Invasive Breast Carcinomas and Related Metastases.

Journal: Cancers

Published: February 22, 2023

RASSF1A-Mediated Suppression of Estrogen Receptor Alpha (ERα)-Driven Breast Cancer Cell Growth Depends on the Hippo-Kinases LATS1 and 2.

RASSF1A-Mediated Suppression of Estrogen Receptor Alpha (ERα)-Driven Breast Cancer Cell Growth Depends on the Hippo-Kinases LATS1 and 2.

Journal: Cells

Published: June 18, 2021

Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2- Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2- Breast Cancer.

Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2- Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2- Breast Cancer.

Journal: Cancers

Published: April 01, 2021

IER2-induced senescence drives melanoma invasion through osteopontin.

IER2-induced senescence drives melanoma invasion through osteopontin.

Journal: Oncogene

Published: October 13, 2020

RASSF1A Suppresses Estrogen-Dependent Breast Cancer Cell Growth through Inhibition of the Yes-Associated Protein 1 (YAP1), Inhibition of the Forkhead Box Protein M1 (FOXM1), and Activation of Forkhead Box Transcription Factor 3A (FOXO3A).

RASSF1A Suppresses Estrogen-Dependent Breast Cancer Cell Growth through Inhibition of the Yes-Associated Protein 1 (YAP1), Inhibition of the Forkhead Box Protein M1 (FOXM1), and Activation of Forkhead Box Transcription Factor 3A (FOXO3A).

Journal: Cancers

Published: August 26, 2020

Improved detection of sentinel lymph node metastases allows reliable intraoperative identification of patients with extended axillary lymph node involvement in early breast cancer.

Improved detection of sentinel lymph node metastases allows reliable intraoperative identification of patients with extended axillary lymph node involvement in early breast cancer.

Journal: Clinical & experimental metastasis

Published: April 19, 2020

Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity.

Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity.

Journal: EMBO molecular medicine

Published: December 16, 2019

Spatiotemporally controlled induction of gene expression in vivo allows tracking the fate of tumor cells that traffic through the lymphatics.

Spatiotemporally controlled induction of gene expression in vivo allows tracking the fate of tumor cells that traffic through the lymphatics.

Journal: International journal of cancer

Published: May 13, 2019

LIPG-promoted lipid storage mediates adaptation to oxidative stress in breast cancer.

LIPG-promoted lipid storage mediates adaptation to oxidative stress in breast cancer.

Journal: International journal of cancer

Published: April 06, 2018

Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells.

Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells.

Journal: Oncotarget

Published: June 20, 2016

'Normalizing' the malignant phenotype of luminal breast cancer cells via alpha(v)beta(3)-integrin.

'Normalizing' the malignant phenotype of luminal breast cancer cells via alpha(v)beta(3)-integrin.

Journal: Cell death & disease

Published: April 11, 2016

Showing 1-12 of 15

Last Updated: 09/26/2026